Eli Lilly | LLY

Stock Price
727.21
Daily Change
-15.70 -2.11%
Monthly
-2.57%
Yearly
-19.48%
Q3 Forecast
721.17

Peers Price Chg Day Year Date
AbbVie 212.56 -0.44 -0.21% 9.95% Sep/05
Abbott 132.94 0.13 0.10% 16.68% Sep/05
ALKERMES 29.94 1.02 3.53% 11.47% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
AstraZeneca 12,090.00 -98.00 -0.80% -4.89% Sep/06
Baxter International 24.42 0.84 3.56% -37.34% Sep/05
Biogen 140.67 0.73 0.52% -30.02% Sep/05
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
GlaxoSmithKline 1,476.00 7.00 0.48% -10.63% Sep/05
Glaxosmithkline 40.50 0.89 2.25% -7.26% Sep/05
J&J 178.43 -0.33 -0.18% 8.51% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
Medtronic 92.93 0.13 0.14% 3.32% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Neurocrine Biosciences 144.10 3.70 2.64% 19.91% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Novo Nordisk A/S 350.00 -10.50 -2.91% -60.30% Sep/05
Novartis 129.82 1.34 1.04% 11.22% Sep/05
Prestige Brands 65.05 -1.70 -2.55% -12.50% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Perrigo 23.49 -0.25 -1.05% -19.14% Sep/02
Drreddys Laboratories 14.34 0.19 1.34% -81.89% Sep/05
Regeneron Pharmaceuticals 573.38 6.16 1.09% -49.30% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
Sanofi 79.50 0.54 0.68% -24.83% Sep/06
Sanofi 46.50 1.18 2.60% -19.47% Sep/05
United Therapeutics 400.52 20.05 5.27% 15.88% Sep/05
Zoetis 153.32 0.12 0.08% -19.13% Sep/05

Indexes Price Day Year Date
US500 6481 -20.59 -0.32% 19.84% Sep/05

Eli Lilly traded at $727.21 this Friday September 5th, decreasing $15.70 or 2.11 percent since the previous trading session. Looking back, over the last four weeks, Eli Lilly lost 2.57 percent. Over the last 12 months, its price fell by 19.48 percent. Looking ahead, we forecast Eli Lilly to be priced at 721.17 by the end of this quarter and at 703.37 in one year, according to Trading Economics global macro models projections and analysts expectations.

Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products include Cymbalta, Emgality, Reyvow, Strattera and Zyprexa. Its Oncology products include Alimta, Cyramza, Erbitux and Verzenio. Other product includes Cialis, for the tratment of erectile dysfunction and benign prostatic hyperplasia. The Company manufacture and distribute its products through facilities in the United States, Puerto Rico, and 8 other countries. Its products are sold in approximately 120 countries.